NCT00028964 is a Phase 1/Phase 2 clinical trial of Chinese herbs in Breast Cancer, sponsored by University of California, San Francisco.

Who is sponsoring NCT00028964?

NCT00028964 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT00028964?

Interventions in NCT00028964: Chinese herbs, cyclophosphamide, doxorubicin hydrochloride, adjuvant therapy.

What condition does NCT00028964 study?

NCT00028964 studies Breast Cancer, Drug/Agent Toxicity by Tissue/Organ.

Is NCT00028964 still recruiting?

NCT00028964 is currently completed. Last updated 20 February 2011.

Last reviewed 2011-02-20 · How we verify

NCT00028964

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double Blind, Pacebo-Controlled Study to Assess The Feasibility, Toxicity And Efficacy (Phase I/II) Of A Chinese Herbal Therapy (CHT) For Symptom Management In Women Undergoing Chemotherapy For Stage I/II/III Breast Cancer

Completed Phase 1/Phase 2 Last updated 20 February 2011

What this trial tests

Phase 1/Phase 2 trial testing Chinese herbs in Breast Cancer. Completed in 1 February 2005.

Timeline

1 February 2001

1 February 2005

Quick facts

Lead sponsor	University of California, San Francisco
Phase	Phase 1/Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Masking	double
Primary purpose	supportive care
Start date	1 February 2001
Estimated completion	1 February 2005
Sites	1 location across United States

Drugs / interventions tested

Chinese herbs
cyclophosphamide (cyclophosphamide) — full drug profile →
doxorubicin hydrochloride — full drug profile →
adjuvant therapy — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Drug/Agent Toxicity by Tissue/Organ — all drugs for Drug/Agent Toxicity by Tissue/Organ →

Sponsor

University of California, San Francisco

Who can join

18 and older, female only, with Breast Cancer or Drug/Agent Toxicity by Tissue/Organ. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Herbs used in traditional Chinese medicine may decrease the side effects of chemotherapy. PURPOSE: Randomized phase I/II trial to study the effectiveness of herbs used in traditional Chinese medicine in decreasing the side effects of chemotherapy after surgery in women who have stage I, stage II, or early stage III breast cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence.
Lin SR, Chang CH, Hsu CF, Tsai MJ, et al · · 2020 · cited 273× · PMID 31368509 · DOI 10.1111/bph.14816

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00028964 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 20 February 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00028964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing